# Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

REPROS THERAPEUTICS INC. Form 8-K		
September 07, 2016		
UNITED STATES SECURITIES AND EXCHANGE Control Washington, D.C. 20549	OMMISSION	
Form 8-K		
CURRENT REPORT		
Pursuant to Section 13 or 15(d) of th	e Securities Exchange Act of 1934	
Date of Repor	t (Date of earliest event Reported): Septe	ember 7, 2016
(Exa	Repros Therapeutics Inc. ct Name of Registrant as Specified in Ch	arter)
<b>Delaware</b> (State or Other Jurisdiction of Incorporation)	<b>001-15281</b> (Commission File Number)	<b>76-0233274</b> (I.R.S. Employer Identification Number)
2408 Timberloch Place, Suite B-7, Texas 77380	The Woodlands,	
(Address of Principal Executive Of		
(Regi	(281) 719-3400 strant's telephone number, including area	ı code)
	, , , , , , , , , , , , , , , , , , ,	,
(Former n	ame or former address, if changed since	last report)
Check the appropriate box below if the the registrant under any of the following	Form 8-K filing is intended to simultane g provisions:	eously satisfy the filing obligation of
[ Written communications pursuant t	to Rule 425 under the Securities Act (17	CFR 230.425)
] [ Soliciting material pursuant to Rule	e 14a-12 under the Exchange Act (17 CF	R 240.14a-12)
Pre-commencement communication	ns pursuant to Rule 14d-2(b) under the E	Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communication	ns pursuant to Rule 13e-4(c) under the E	xchange Act (17 CFR 240.13e-4(c))

]

## Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

### Item 7.01. Regulation FD Disclosure.

On September 7, 2016, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

#### Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1. Press release dated September 7, 2016

## Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Repros Therapeutics Inc.** 

Date: September 7, 2016 By: /s/ Kathi Anderson

Kathi Anderson

**CFO**